MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14760584.2026.2708199

Медицинская библиотека · Expert review of vaccines · 2026

Cost-effectiveness of RSVpreF for the prevention of respiratory syncytial virus illness among high-risk adults in Germany.

Quinn Erin, MacKinnon Mary, Freisberg Severin, Lade Caroline, Friedrich Josephine, Bayer Lea J, von Eiff Christof, Averin Ahuva, Sato Reiko, Schiffner-Rohe Julia

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Vaccination against lower respiratory tract illness due to respiratory syncytial virus (RSV-LRTI) is approved in Europe for all adults aged ≥18 years. The German Standing Committee on Vaccination (STIKO), however, only recommends vaccination for high-risk adults aged 60-74 years and all adults aged ≥75 years (standard of care [SOC]). Younger, immunocompromised adults [IC], as well as those with chronic medical conditions [CMC+], remain unprotected.

RESEARCH DESIGN AND

METHODS

A multi-cohort model projected lifetime RSV-related clinical and economic outcomes (in 2025 €) among adults in Germany. Base case analyses considered the cost-effectiveness of adding vaccination of IC adults aged 18-59 years to the SOC from a societal perspective. An expanded base case adding CMC+/IC adults aged 18-59 years to the SOC was also evaluated.

RESULTS

Adding IC adults aged 18-59 years to the recommendation would prevent 6,490 additional cases, avert 199 more deaths, and reduce costs by 21 million € compared to the SOC. Incorporating CMC+/IC adults would prevent 24,545 additional cases and 388 deaths, at an incremental cost of 238 million €.

CONCLUSIONS

Expanding the recommendation to include IC or CMC+/IC adults aged 18-59 years could substantially reduce the clinical burden of RSV-LRTI in Germany; including IC 18-59-year-olds would also be cost-saving.

Для цитирования: Quinn Erin, MacKinnon Mary, Freisberg Severin, Lade Caroline, Friedrich Josephine, Bayer Lea J, von Eiff Christof, Averin Ahuva, Sato Reiko, Schiffner-Rohe Julia. Cost-effectiveness of RSVpreF for the prevention of respiratory syncytial virus illness among high-risk adults in Germany.. Expert review of vaccines. 2026. DOI: 10.1080/14760584.2026.2708199.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.